Brimonidine (Alphagan®): A clinical profile four years after launch

European Journal of Ophthalmology

Volumn 11, Issue SUPPL. 2, 2001, Pages

  David, R ^a  

^a Ophthalmology Clinical Research   (United States)

Author keywords

Brimonidine; Clinical trials; Glaucoma

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; TIMOLOL; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; QUINOXALINE DERIVATIVE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; META ANALYSIS; PRIORITY JOURNAL; SUBSTITUTION THERAPY; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; REVIEW; SAFETY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; CLINICAL TRIALS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-2; SAFETY; TIMOLOL;

EID: 0034754426     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210101102s10     Document Type: Conference Paper

References (22)

1. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial
2. Clinical experience with brimonidine 0.2% and timolol 0.5% in gaucoma and ocular hypertension
3. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension
4. Brimonidine tartrate 0.2% twice daily vs timolol 0.5%: 1-year results in glaucoma patients
5. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
6. Ongoing assessment of the safety profile and efficacy of brimonidine compared with timolol: Year-three results
7. The evolving pharmacotherapeutic profile of brimonidine, an alpha-2-adrenergic agonist, after four years of continuous use
8. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol
9. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy
10. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: A randomized clinical trial
11. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension
12. Additivity of brimonidine 0.2% b.i.d, or pilocarpine 2% t.i.d. to beta-blocker monotherapy
13. Comparison of the efficacy and tolerability of Alphagan and Trusopt as adjunct therapy with beta-blockers in patients with chronic open-angle glaucoma or ocular hypertension
14. Efficacy and tolerability of Alphagan versus Xalatan as adjunct therapy in chronic open-angle glaucoma or ocular hypertension patients uncontrolled on beta-blockers alone
15. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma
16. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension
17. Measuring the impact of glaucoma and its treatment on quality of life: The Glaucoma Disability Index
18. A two month evaluation of Alphagan alone compared to patient's previous two line therapy
19. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma
20. Apparent central nervous system depression in infants after the use of topical brimonidine
21. Developing brain as a target of toxicity
22. In vivo age-related changes in hepatic drug-oxidizing capacity in humans